Pages that link to "Q37415341"
Jump to navigation
Jump to search
The following pages link to Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group (Q37415341):
Displaying 50 items.
- Targeted therapy in advanced bladder cancer: what have we learned? (Q27009469) (← links)
- Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma (Q28084715) (← links)
- Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy (Q30563774) (← links)
- Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder (Q30857433) (← links)
- A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer (Q33409364) (← links)
- PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. (Q33413496) (← links)
- Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer. (Q33431429) (← links)
- Systemic therapy in bladder cancer (Q33578564) (← links)
- Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer (Q33923405) (← links)
- Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. (Q34438928) (← links)
- Multiple mechanisms mediate resistance to sorafenib in urothelial cancer (Q34685436) (← links)
- Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer (Q35040383) (← links)
- Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective study (Q35811446) (← links)
- Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer (Q35998718) (← links)
- Personalized therapy for urothelial cancer: review of the clinical evidence (Q36062762) (← links)
- Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review (Q36270115) (← links)
- Novel strategies for treating relapsed/refractory urothelial carcinoma (Q36995686) (← links)
- New therapeutic targets in the management of urothelial carcinoma of the bladder (Q37308633) (← links)
- Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer (Q37702430) (← links)
- Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise (Q37763156) (← links)
- Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium (Q37764163) (← links)
- Angiogenesis as a therapeutic target in urothelial carcinoma (Q37781665) (← links)
- Vinflunine in the treatment of advanced bladder cancer (Q37821892) (← links)
- Meta-analysis of dermatological toxicities associated with sorafenib (Q37867169) (← links)
- Current chemotherapeutic strategies against bladder cancer (Q37888549) (← links)
- Current treatment of metastatic bladder cancer and future directions (Q37960909) (← links)
- Urothelial cancers: using biology to improve outcomes (Q37965638) (← links)
- Novel molecular targets for the therapy of urothelial carcinoma (Q38003195) (← links)
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. (Q38028124) (← links)
- Novel immunotherapies in GU malignancies (Q38092022) (← links)
- Targeting molecular aberrations in urothelial carcinoma: are we almost there? (Q38110043) (← links)
- Molecular targets on the horizon for kidney and urothelial cancer (Q38132039) (← links)
- Second-line systemic therapy for metastatic urothelial carcinoma of the bladder (Q38155201) (← links)
- Sunitinib malate in the treatment of urothelial cancer (Q38159713) (← links)
- Emerging drugs for urothelial carcinoma (Q38160271) (← links)
- New treatments for bladder cancer: when will we make progress? (Q38177753) (← links)
- Targeted therapies in urothelial carcinoma. (Q38200798) (← links)
- The route to personalized medicine in bladder cancer: where do we stand? (Q38337192) (← links)
- The role of genomics in the management of advanced bladder cancer (Q38342992) (← links)
- Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond. (Q38424919) (← links)
- Targeting the VEGF pathway in metastatic bladder cancer (Q38534167) (← links)
- Systemic therapy for metastatic bladder cancer in 2016 and beyond (Q38753358) (← links)
- Incorporating VEGF-targeted therapy in advanced urothelial cancer (Q38756931) (← links)
- Improving Systemic Chemotherapy for Bladder Cancer (Q38777610) (← links)
- Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU). (Q38798645) (← links)
- Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells (Q39200090) (← links)
- Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells (Q39677393) (← links)
- Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells (Q41078957) (← links)
- Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. (Q41770394) (← links)
- Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05) (Q43718098) (← links)